Special Issue

Parasitic Infections: Therapy for Host Immunity and Vaccination

Message from the Guest Editors

Over the last few decades, there has been extensive research into pharmaceutical alternatives to deal with adverse effects caused by parasites in humans and animals. This is mainly due to the development of resistance to antiparasitic drugs and the ecological problems associated with pharmacological residues in the environment and animal products for human consumption. However, there are still very few tools available to address more complex parasitic groups. such as helminths and arthropods. Many alternative strategies focus on enhancing the immune response of hosts to reduce parasite development. However, the results have not always been as expected, possibly due to the complexity of host-parasite interactions and environmental involvement. We welcome original manuscripts, reviews, brief communications, metaanalyses, and other types of articles reporting vaccination and therapy trials against parasites for a Special Issue in Vaccines. We encourage the analysis of immune mechanisms against parasites and the relationship between protection and antiparasitic control strategies.

Guest Editors

Prof. Dr. José Manuel Molina Caballero

Department of Animal Pathology, Faculty of Veterinary Medicine, University of Las Palmas de Gran Canaria, Gran Canaria, Spain

Dr. Antonio Ruiz Reyes

Department of Animal Pathology, Faculty of Veterinary Medicine, University of Las Palmas de Gran Canaria, Gran Canaria, Spain

Deadline for manuscript submissions

closed (31 July 2025)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/195451

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

